INTRODUCTION
The mucosal immune system in the female reproductive tract must be uniquely prepared to maintain the balance between commensal microbiota, sexually transmitted pathogens and spermatozoa. Females mount more vigorous antibody-and cellmediated immune responses than males following infection or vaccination. [1] [2] [3] [4] [5] However, increased immunity in females is a double-edged sword: its beneficial effects against infectious diseases are countered by the greater possibility of autoimmune diseases. [6] [7] [8] Furthermore, in order to be compatible with reproduction, immune responses against allogeneic sperm or the semi-allogeneic zygote must be prevented. The hormonal changes associated with the ovarian cycle also correlate with deviations in immunity. 9 17b-estradiol (E2) and progesterone (Pg) exert a powerful effect in many areas, including the central nervous system and the immune response. 10 It has been proposed that, in a normal ovarian cycle, the window of vulnerability that opens after ovulation to enable survival of foreign spermatozoa and the allogeneic embryo can leave females more susceptible to infection. 11 Dendritic cells (DCs), which are professional antigen-presenting cells, reside in the mucosa. 12, 13 DCs sample the environment looking for exogenous antigens using various pattern-recognition receptors (PRRs), which recognize and bind to specific molecules on the surface of pathogens. 14, 15 Upon contact with exogenous ligands or danger signals, DCs migrate to draining lymph nodes, thereby carrying the antigens to T-cell-rich areas to promote T-cell activation and polarization. 12, 16, 17 Recognition of exogenous molecules through PRRs results in the translocation of the nuclear factor-kb (NF-kb) from the cytoplasm to the nucleus.
Ikbkg is the regulatory subunit of the inhibitor of NF-kb kinase (IKK) complex. Nf-kb dimers remain inactive in the cytoplasm by association with Nfkbia. After stimulation, the IKK complex phosphorylates Nfkbia and undergoes proteasomal degradation. Free Nf-kb can then translocate into the nucleus and stimulate the transcription of target genes. 18 This translocation step is necessary for the promotion of the DC maturation program that induces migration and ends with the antigen presentation to the T cells in the lymph nodes. 19, 20 We and other authors have reported that E2-treated DCs failed to mature and promote the immune response during pregnancy [21] [22] [23] [24] [25] [26] and estrus. 25, 26 E2 treatment during ovulation downregulates toll-like receptor (TLR) signaling from microbial product, 25 and this in turn leads to lower translocation of the transcription factor NF-kb, 21 reduced upregulation of CD197 (CCR7) expression and impaired migration in response to the chemokine CCL21, which is implicated in lymph node homing of DCs.
26 E2-treated DCs also have lower levels of costimulatory molecules and lower expression of antigen presentation proteins, as well as impaired induction of the immune response. 25, 26 However, the molecular mechanism(s) whereby sex hormones influence the immune system remains undetermined.
The biological actions of estrogen are mediated through association of the E2 receptor proteins with the estrogenresponsive elements (EREs) in the promoters of E2-regulated genes. 10, 27 To further investigate the molecular mechanism by which E2 downregulates DC functions, we analyzed the expression of genes whose regulatory regions contain EREs. We identified genes that were common to the three published genome-wide ERE promoter databases [28] [29] [30] and focused on those associated with inflammation and DC maturation in order to create a sizable experimental database. Here, we demonstrate that the concentration of E2 at estrus downregulates NF-kb translocation to the nucleus, a step that is crucial for the DC maturation process, 20 owing to the transcriptional downregulation of Ikbkg expression at the promoter level in DCs.
RESULTS AND DISCUSSION

E2 downregulates Ikbkg expression in DCs
We performed quantitative PCR to determine whether expression of the selected genes was regulated by E2 at the estrus concentration in DCs. We did not detect significant differences in the expression of the selected genes containing EREs in their gene promoter (for example, Nfkbia, Cebpb, Fos, Tradd and Mapk3) between vehicle-treated and E2-treated DCs (Figures 1a and b) . However, E2-treated DCs showed significantly reduced expression of the Ikbkg gene (also known as NEMO or Ikkg), whereas no significant differences were observed after treatment with Pg or diestrus-E2 (Figure 1c) . Moreover, testing of Ikbkg expression in CD4 þ T cells did not reveal significant differences in expression ( Figure 1d ). Next, we tested Ikbkg expression in other DC subtypes and observed reduced Ikbkg expression in estrus-E2-treated bone marrow-derived DCs (BMDCs) and in spleen DC CD11c þ /CD8 þ and CD11c þ /CD4 þ sub-populations, whereas in the spleen DC CD11c þ /CD8 -/CD4
-sub-population we found no significant differences with vehicle-treated DCs (Figure 2a ). We also detected the same reduction in mRNA in Ikbkg expression in RAW 264.7 cells treated with estrus-E2 compared with vehicle-treated cells (Figure 2a) . In addition, we tested Ikbkg expression by flow cytometry and western blot in RAW cells. We observed a reduction in Ikbkg expression in estrus-E2-treated cells, whereas diestrus-E2-treated cells showed a lesser effect. By contrast, no significant differences were found in Ikbkg expression in the Pg-treated and diestrus-E2/Pg mixture-treated cells compared with the vehicletreated cells (Figures 2b-e) . These results indicate that E2 downregulates expression of Ikbkg.
Estrus-E2 treatment downregulates NF-kb translocation
Ikbkg is the regulatory subunit of the inhibitor of the IKK complex, and cells defective in Ikbkg do not activate NF-kb. 18 Because of the central role of Ikbkg in this pathway, we reasoned that, during ovulation, E2 could downregulate Ikbkg expression in DCs to lower their efficiency and allow the spermatozoa to survive in the female reproductive tract. To test that hypothesis, we treated BMDCs with vehicle or E2 and pulsed them with well-known maturation stimuli such as lipopolysaccharide (LPS) or Candida albicans. Cells were stained with a p65 subunit of NF-kb antibody and analyzed using confocal microscopy. Vehicle-treated DCs pulsed with C. albicans showed an NF-kb antibody signal concentrated in the nucleus. However, estrus-E2 treatment produced disperse cytosolic NF-kb staining in most of the DCs analyzed (Figures 3a-c) . Similar stains were observed in non-pulsed DCs. We also analyzed LPS-treated DCs and detected the same lower NF-kb translocation to the nucleus in the E2-treated cells compared with the vehicle-treated cells (Figure 3d ). To further investigate the effect of E2 on the NFkb pathway, we transiently transfected HEK293-TLR2 cells with the NF-kb-Luc plasmid and treated them with vehicle or estrus-E2. Finally, we pulsed the cells with TLR2 ligands to induce NF-kb translocation. Pre-treatment with estrus-E2 lowered the NF-kbinduced luciferase signal compared with cells pretreated with vehicle, lipoteichoic acid and Pam3Cys-Ser-Lys4 (Pam3C) (Figures  3e and f) . The results of our experiments suggest that pretreatment with estrus-E2 downregulates TLR signaling and NF-kb translocation. nucleus, which is necessary for upregulation of the antigen presentation proteins and promotion of T-cell activation and polarization. 12, 19 To test the kinetics of Ikbkg transcription upon stimulation of DCs, we pulsed vehicle-or E2-treated CD11c spleen DCs with LPS. After treatment with LPS, Ikbkg expression was downregulated in the vehicle-treated DCs. Conversely, E2-treated cells showed an early increase in Ikbkg expression; however, after 3 h of treatment, Ikbkg expression was lower in the E2-treated cells than in the vehicle-treated DCs (Figure 4a ). To correlate the effects of estradiol on Ikbkg transcription and NF-kB translocation, we treated CD11c þ spleen DCs with LPS for 48 h and analyzed Cd86 and MHC II expression in the spleen DC subsets. We detected reduced expression of Cd86 and MHC II in the E2-treated CD11c þ /CD4 þ and CD11c þ /CD8 þ cells compared with the vehicle-treated cells (Figures 4b and c) . We also tested expression of Ifng, Il1b, Il23 and Il6 in spleen DC subsets after the LPS treatment; cytokines expression was different in every subset, but the cytokines profile expression was lower in the E2-treated CD11c þ /CD8 þ cells than in the vehicle-treated cells (Figure 4d ). In order to investigate the effect of E2 on T-cell activation by DC, we treated CD11c þ spleen DCs with hormones before pulsing them with C. albicans. Next, we added CD4 þ T cells obtained from mice immunized with C. albicans. We detected lower Il17 levels in the E2-treated coculture supernatants (Figure 4e ). In summary, the lower Ikbkg expression and Nf-kb translocation in the E2-treated DCs correlated with lower antigen presentation protein values, inflammatory cytokine production and reduced stimulation of T cells. Thus, we can conclude that E2 induces downregulation of the molecular DC activation program and that the failure of the estrus-E2-treated DCs to mature 25, 26 might be due to inappropriate NF-kb translocation induced by lower Ikbkg expression.
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Estrus-E2 regulates repression of the Ikbkg promoter in DC In order to elucidate the molecular mechanism underlying lower Ikbkg expression in estrus-E2-treated DCs, we hypothesized that the E2 receptor could bind the Ikbkg gene promoter and downregulate its expression. Ikbkg has four alternative transcriptional start sites that produce eight mRNAs and three different ATG-initiation sites (Figure 5a ). We designed primers to test which of the transcriptional start sites activities were downregulated by treatment with E2. We detected downregulation of the TSb in RAW cells treated with estrus-E2 (Figure 5b ), and downregulation of Ikbkg TSb and TSd in spleen DCs (Figure 5c ). Next, we tested the effect of estrus-E2 treatment on TSb and TSd expression in different DC sub-populations. We detected lower expression of Ikbkg TSb than TSd in BMDCs. Moreover, similar reductions were detected in spleen DC CD11c þ /CD8 þ cells, whereas the CD11c þ /CD4 þ and CD11c þ /CD8 -/CD4 -cells did not show strong differences (Figure 6a and Supplementary Figure 1a) . Our data show that TSb is strongly downregulated in estrus-E2-treated BMDCs, CD11c þ /CD8 þ spleen DCs and RAW cells. Therefore, we conclude that TSb could be a key element in regulation of the Ikbkg gene promoter. Two putative ERE-binding sites, ERE1 (-2478  5 0 -AGGTCATCATGACAC)-3 0 and ERE2 (-1881 5 0 -AGGTCACATT GAGCT)-3 0 , were identified between TSb (-3215) and the ATG1 ( þ 1). Therefore, we cloned the fragment containing TSb with ERE1 and 2 into the pXP2 plasmid (PIkbkg WT pXP2) and we transfected RAW cells. Treatment with estrus-E2 downregulated the luciferase activity of the plasmid PIkbkg WT pXP2 compared with vehicle-treated transfected cells. Conversely, diestrus-E2 and Pg did not have an effect (Figure 6b ). We also cloned fragment -4092 to -2020, which contains the TSb without ERE2 (PIkbkg -ERE2 pXP2), and the downregulation of the luciferase activity of the E2-treated cells was the same. Then, we cloned fragment -4092 to -2991, which contains TSb without ERE1 and 2 (PIkbkg -EREs pXP2), and the downregulation of the luciferase activity of the E2-treated cells disappeared. We then mutated both ERE1 (PIkbkg ERE1mut pXP2) and ERE2 (PIkbkg ERE2mut pXP2). While mutation of ERE2 had no effect, mutation of the ERE1-binding site abrogated E2-dependent downregulation in luciferase activity (Figure 6c) . Therefore, ERE1 has a central role in the regulation of repression of the Ikbkg promoter in DCs during estrus. Our data add a new piece to the puzzle by showing the molecular mechanism, namely, that E2-treated DCs have lower Ikbkg expression, thus explaining why they are not able to trigger the appropriate DC maturation program. The molecular mechanism we propose is in accordance with previously reported data, which show that partial reduction of Ikbkg expression by specific siRNA reduced NF-kb translocation. 31 Moreover, patients with ectodermal dysplasia associated with immunodeficiency have hypomorphic Ikbkg mutations (partially disrupted expression or activity) resulting in impaired NF-kb translocation and immunodeficiency due to lack of DC maturation. 32, 33 The natural effect of E2 on DCs may constitute an adaptation to reconcile the strong female immune response with reproductive function. Successful pregnancy requires that spermatozoa enter the oviduct while surviving the threat of the immune response. In most mammalian species, this involves binding of allograft spermatozoa to the oviductal epithelium for several days, 34, 35 and as ovulation approaches, the sperm in the reservoir undergo capacitation and acquire the ability to fertilize the oocyte. 35 E2-treated DCs would not trigger the maturation program, migrate to the T-cell areas, and upregulate antigen presentation proteins during estrus (high E2). Therefore, allogeneic spermatozoa could reach and be stored at the oviduct in order to acquire the ability to fertilize. During diestrus, DCs would recover their energetic state, because it has been shown that Pg-treated DCs increase their expression of antigen-presenting proteins, decrease phagocytosis and increase the efficacy of T-cell stimulation 36, 37 to restore the equilibrium. In conclusion, we propose that, during ovulation, E2 levels open a window of vulnerability by inducing Ikbkg downregulation in DCs in order to reduce efficiency so that spermatozoa can survive. This may represent an adaptation to reconcile the female immune response with reproductive function. 
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MATERIALS AND METHODS Mice
Female BALB/c (H-2d) mice were maintained under specific pathogen-free conditions in the Animal Facility of Instituto de Investigació n Sanitaria Gregorio Marañ ó n. Procedures involving animals and their care were conducted in conformity with national and international laws and policies. The Instituto de Investigació n Sanitaria Gregorio Marañ ó n Animal Care and Use Committee approved all the procedures described. Females were immunized by peritoneal injection twice with 500 ml of PBS containing 5 Â 10 5 yeast cells every 20 days. 26 Spleen DCs and CD4 þ T-cell purification Spleens were dissected, and splenocytes were isolated. 26 Spleen DCs were purified using the CD11c MicroBeads mouse kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD4 þ and CD8 þ DCs were purified using the CD4 þ Dendritic Cell Isolation Kit and the CD8 þ DCs Isolation Kit (Miltenyi Biotec). CD4 þ spleen T cells were purified using the CD4 þ T Cell Isolation Kit (Miltenyi Biotec) following the manufacturer's instructions. Cells were plated on 24-well plates containing RPMI 1640 without phenol red medium (10% heat-inactivated FCS (non-charcoal-dextran stripped), 1 mM sodium pyruvate, 1% amino acids, 2 mM L-glutamine, 50 mM 2-ME and 15 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)) complemented with hormones dissolved in ethanol for 12 h to adjust for the duration of estrus. In the maturation experiments, 1 mg ml À 1 LPS (Escherichia coli 0111:B4 LPS Ultrapure; InvivoGen, San Diego, CA, USA ) was added for 24 h.
Hormonal treatment E2 or Pg (Calbiochem, Darmstadt, Germany) were dissolved in ethanol at physiological range concentrations, 38, 39 as follows: E2-estrus, 10 À 10 M; E2-diestrus, 10 À 11 M; and Pg 10 À 8 M. Cells were treated for 12 h to adjust to the duration of estrus in mice.
Production of BMDCs
Bone marrow cells were flushed out from femurs and tibias and plated onto wells equipped with round cover slips. BMDCs were generated as previously described. 26 Briefly, bone marrow cells were cultured in RPMI 1640 without phenol red medium (10% heat-inactivated FCS (non-charcoal-dextran stripped), 1 mM sodium pyruvate, 1% amino acids, 
RNA extraction, reverse transcription and quantitative PCR analysis
Total RNA was extracted from cell pellets using an RNeasy Micro Kit (Qiagen, Germantown, MD, USA) and converted to complementary DNA using a SuperScript kit (Applied Biosystems, Foster City, CA, USA). 26 Quantitative PCR was performed in MicroAmpTM Optical 96-well reaction plate (Applied Biosystems) in quadruplicate for each complementary DNA. PCR reactions were run on a StepOne Plus device (Applied Biosystems). The gene-specific primers used are shown in Table 1 . Data were collected and analyzed using StepOne v2.2 (Applied Biosystems). The comparative delta-delta Ct Method ( DD Ct) was used to calculate statistical significance between the independent experiments (Data Assist v2.0, Applied Biosystems). Pgk1 and Tmem189 were used for normalization. Data were normalized to vehicle treatment.
Immunoblot
RAW cells were treated with the hormones for 24 h, collected and washed in PBS, and proteins were extracted in radioimmunoprecipitation assay (RIPA) buffer. Thirty micrograms of the extracts were resolved in 10% SDS-polyacrylamide gel electrophoresis, transferred to a PVDF membrane (BIO-RAD, Hercules, CA, USA), and probed with rabbit anti-mouse p65/relA NF-kb (AbD Serotec, Dusseldorf, Germany), polyclonal NEMO (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-b-Actin (Sigma clone AC-15). Proteins were detected with peroxide-coupled anti-rabbit or anti-mouse IgG (Amersham-Pharmacia Biotech, Piscataway, NJ, USA) using ECL reagents (GE Healthcare Europe GmbH, Freiburg, Germany). We used RAW cells in this experiment to follow the Three Rs of humane animal experimentation and reduce the number of animals used in the experiments.
C. albicans culture, staining and confocal microscopy The SC5314 C. albicans strain was grown on Sabouraud dextrose chloramphenicol agar plates (Conda, Madrid, Spain) overnight at 30 1C before the experiments. For staining, C. albicans were collected, washed and labeled with Oregon Green 488 or FITC. 26 BMDCs were challenged with labeled C. albicans at an multiplicity of infection of 5 for 30 min. Cells were washed, fixed, permeabilized with 0.2% saponin and stained with the rabbit polyclonal anti NF-kb (AbD serotec). Confocal microscopy images were collected using a Leica TCS SP2 AOBS microscope. The percentage of co-localization was calculated manually or using the Image J software system.
Transfection and luciferase assay ) and lipoteichoic acid (1 mg ml À 1 ). After 3-5 h of incubation, cells were harvested and lysed and luciferase activity was determined using the Luciferase Assay System Kit (Promega, Madison, WI, USA). Transfection efficiencies were normalized by co-transfection with the b-galactosidase expression plasmid pCMV-bgalactosidase and b-galactosidase levels were determined using the Galacto-Light kit (Applied Biosystems, Warrington, UK).
Nemo promoter cloning, deletions and mutants
Wild-type mouse Ikbkg-1133-4092 ATG1 promoter was cloned from BALB/c mice genomic DNA into PXP2 vector using BamH1 and XhoI restriction sites. Site mutations were introduced in the Ikbkg-1133-4092-ATG1-PXP2-Luc promoter with the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The primers used for the cloning and mutations are shown in Table 2 . DNA constructs and mutations were confirmed by DNA sequencing. Estradiol downregulates Ikbkg expression S Lasarte et al
